TriSalus Life Sciences Inc KOL Event (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Nelson Cox - Lake Street Capital Markets LLC - Analyst : Hey. Thanks for taking the questions and I appreciate the presentation and time today. It was very comprehensive. Dr. Camacho, just maybe to start, how many thyroid embolization procedures are you currently completing approximately per month? And then how many of these in your practice makes sense -- would it make sense to use the TriNav versus just a standard end-hold catheter?

Question: Nelson Cox - Lake Street Capital Markets LLC - Analyst : Okay. That's helpful. And then we walked through some of the benefits and risks of TAE versus surgery, which looks very supportive of embolization. But can you walk through what you think is most needed for this to become a standard of care in practice? What do you hear out there in the field with your peers. And I know you talked a little bit about guidelines and more clinical data, but just any other color there would be helpful.

Question: Nelson Cox - Lake Street Capital Markets LLC - Analyst : All right. Very helpful. Thank you for the time today.

Question: Carl Byrnes - Northland Securities Inc - Analyst : Thanks. Thanks for the question. I hope you can hear me. In real-world practice, do you see adoption of TAE being driven more from endocrinologists referrals or through interventional radiologists?

Question: Carl Byrnes - Northland Securities Inc - Analyst : Excellent. That's great. Thanks much.